Loading clinical trials...
Loading clinical trials...
HRV-Guided tDCS: Integrating A Biomarker For Clinical Utility
This technology development project will be informed and guided by initial data collection of human subject data. For this purpose, the investigators will recruit n=100 people with mild to moderate depression in a double-blinded, parallel-arm, sham-controlled data collection period administered at home and using the investigator's remotely supervised (RS) tDCS protocol. Enrolled participants will complete 10 days of 30-minute tDCS (2.0, DLPFC left anodal) using the RS-tDCS protocol. During each daily session, standard HR and impedance-based HR (i-HR), obtained from the tDCS headset, will be collected to identify a possible marker of response to tDCS in depression. Participants will be randomized 2:1 to active vs. sham tDCS.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
NYU Langone Health
New York, New York, United States
Start Date
January 2, 2025
Primary Completion Date
November 1, 2027
Completion Date
November 1, 2027
Last Updated
November 28, 2025
100
ESTIMATED participants
Active Transcranial Direct Current Stimulation (tDCS)
DEVICE
Sham Transcranial Direct Current Stimulation (tDCS)
DEVICE
Lead Sponsor
NYU Langone Health
Collaborators
NCT07360600
NCT06793397
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions